0001209191-21-024893.txt : 20210402 0001209191-21-024893.hdr.sgml : 20210402 20210402210011 ACCESSION NUMBER: 0001209191-21-024893 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210402 DATE AS OF CHANGE: 20210402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Taylor Stacy L CENTRAL INDEX KEY: 0001799081 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 21803571 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVENUE E SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-31 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001799081 Taylor Stacy L C/O ADAPTIVE BIOTECHNOLOGIES 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102 0 1 0 0 SVP and General Counsel Common Stock 2021-03-31 4 M 0 1042 7.80 A 16078 D Common Stock 2021-03-31 4 M 0 1771 6.55 A 17849 D Common Stock 2021-03-31 4 M 0 1354 31.71 A 19203 D Common Stock 2021-03-31 4 S 0 4167 40.00 D 15036 D Stock Option (Right to Buy) 7.80 2021-03-31 4 M 0 1042 0.00 D 2029-04-23 Common Stock 1042 26042 D Stock Option (Right to Buy) 6.55 2021-03-31 4 M 0 1771 0.00 D 2028-04-24 Common Stock 1771 21250 D Stock Option (Right to Buy) 31.71 2021-03-31 4 M 0 1354 0.00 D 2030-02-13 Common Stock 1354 47396 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Stacy L. Taylor by Eric Billings as attorney-in-fact 2021-04-02